News

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced that the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel,...

International Children's Heart Foundation (ICHF) announced that they will be expanding and nationalizing their program in the Dominican Republic to include Santo Domingo beginning September 2011. ICHF is a non-profit organization dedicated...

Team AFib(TM), a coalition of leading patient advocacy organizations, is unveiling a series of initiatives designed to educate Americans about atrial fibrillation (AFib) and its link to stroke(1) during September's National Atrial...

Stereotaxis, Inc. announced that the results of the Study to Obliterate Persistent Ventricular Tachycardia (STOP-VT) was presented at the European Society of Cardiology (ESC) 2011 Congress held in Paris, France on Sunday, August 28. The...

Promote Quadra CRT-D Offers Physicians the Ability to Address Pacing Complications Without the Need to Surgically Reposition a Lead St. Jude Medical, Inc., a global medical device company, announced the approval of the industry’s first...

HeartSine® Technologies, Inc., a world leader in personal and public access defibrillators, announced that it is a finalist to receive the coveted Orange Innovation Award in the 10th annual UK National Business Awards. HeartSine was selected...

CardioFocus, Inc., developer of the HeartLight™ Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces results from a clinical study representing the first 40 atrial fibrillation patients treated with the...

Study Shows Simpler Version of the Device Gives Same Benefit with Less Risk When it comes to defibrillators, simpler may be safer, even though more complex machines are used on a majority of patients. That's according to a new study from a...

eCardio Diagnostics announced their inclusion on Inc. magazine’s fifth annual Inc. 500|5000, an exclusive ranking of the nation's fastest-growing private companies. eCardio was recognized for the third consecutive year, ranking #912 overall...

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) announced plans to launch RE-ALIGN™, a global, Phase II trial evaluating the safety and pharmacokinetics of dabigatran etexilate in 400 patients who have mechanical heart valves.(1) The...